299 related articles for article (PubMed ID: 8678767)
1. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
2. Staging recurrent metastatic colorectal carcinoma with PET.
Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
[TBL] [Abstract][Full Text] [Related]
3. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
4. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
Zhuang H; Sinha P; Pourdehnad M; Duarte PS; Yamamoto AJ; Alavi A
Nucl Med Commun; 2000 Sep; 21(9):793-8. PubMed ID: 11065150
[TBL] [Abstract][Full Text] [Related]
6. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
7. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
[TBL] [Abstract][Full Text] [Related]
9. [Imaging in the diagnosis of colorectal liver metastases and extrahepatic abnormalities].
Bipat S; van Leeuwen MS; Oyen WJ; Planting AS; IJzermans JN; Stoker J
Ned Tijdschr Geneeskd; 2008 Apr; 152(15):857-62. PubMed ID: 18512524
[TBL] [Abstract][Full Text] [Related]
10. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.
Imdahl A; Reinhardt MJ; Nitzsche EU; Mix M; Dingeldey A; Einert A; Baier P; Farthmann EH
Langenbecks Arch Surg; 2000 Mar; 385(2):129-34. PubMed ID: 10796051
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer.
Beets G; Penninckx F; Schiepers C; Filez L; Mortelmans L; Kerremans R; Aerts R; De Roo M
Br J Surg; 1994 Nov; 81(11):1666-70. PubMed ID: 7827902
[TBL] [Abstract][Full Text] [Related]
12. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
[TBL] [Abstract][Full Text] [Related]
14. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis.
Lake ES; Wadhwani S; Subar D; Kauser A; Harris C; Chang D; Lapsia S
Ann R Coll Surg Engl; 2014 Apr; 96(3):211-5. PubMed ID: 24780786
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
[TBL] [Abstract][Full Text] [Related]
16. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
Fuster D; Lafuente S; Setoain X; Navales I; Perissinotti A; Pavia J; Paredes P; Lomeña F; Pons F
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):111-6. PubMed ID: 22154291
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET.
Rydzewski B; Dehdashti F; Gordon BA; Teefey SA; Strasberg SM; Siegel BA
AJR Am J Roentgenol; 2002 Feb; 178(2):353-8. PubMed ID: 11804891
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease.
Rosa F; Meimarakis G; Stahl A; Bumm R; Hahn K; Tatsch K; Dresel S
Nuklearmedizin; 2004 Aug; 43(4):135-40. PubMed ID: 15316581
[TBL] [Abstract][Full Text] [Related]
19. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
Denecke T; Steffen I; Hildebrandt B; Rühl R; Streitparth F; Lehmkuhl L; Langrehr J; Ricke J; Amthauer H; Hänninen EL
Acta Radiol; 2007 Oct; 48(8):821-30. PubMed ID: 17924212
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
